CRISPR-based innovations drive $21 billion in pharmaceutical licensing deals over five years, reveals GlobalData
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The company will respond to the Warning Letter within the stipulated timelines
A game changing solution for the pharmaceutical industry
Highly effective preservation solutions ensuring the safety and protection of personal care products
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
Subscribe To Our Newsletter & Stay Updated